Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ama Alexis

Allergy & Immunology New York, NY Medical Doctor

NPI 1700978681 CMS profile 31786

49 Murray St, New York, NY 10007

Open in the dashboard

General payments

$119,973

423 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ama Alexis of New York, NY is reported in the CMS Open Payments database as having received $119,973 across 423 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $49,075 122
2024 General $34,645 95
2023 General $15,067 82
2022 General $7,283 31
2021 General $2,249 16
2020 General $6,649 19
2019 General $5,004 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ama Alexis
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Ama Alexis were reported at $49,075. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Ama Alexis Allergy & Immunology median Middle half National median
2019 $5,004 $594 $163–$1,512 $163
2020 $6,649 $426 $106–$1,233 $114
2021 $2,249 $638 $157–$1,708 $132
2022 $7,283 $790 $205–$1,961 $149
2023 $15,067 $852 $220–$2,147 $160
2024 $34,645 $865 $203–$2,267 $164
2025 $49,075 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $34,549 83 payments
  2. Regeneron Healthcare Solutions, Inc. $25,237 58 payments
  3. Pfizer Inc. $14,350 37 payments
  4. Eli Lilly and Company $9,564 10 payments
  5. Dermavant Sciences, Inc. $7,598 5 payments
  6. Incyte Corporation $6,486 16 payments
  7. Lilly USA, LLC $5,833 12 payments
  8. AstraZeneca Pharmaceuticals LP $5,324 34 payments
  9. Genentech USA, Inc. $4,096 11 payments
  10. Janssen Global Services, LLC $1,760 1 payment
  11. Other $5,178 156 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $58,167 29 payments
  2. Consulting Fee $40,383 16 payments
  3. Food and Beverage $13,118 345 payments
  4. Travel and Lodging $5,607 30 payments
  5. Honoraria $2,590 1 payment
  6. Education $108 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $33,397 89 payments
  2. DUPIXENT Inflammation And Immunology $14,300 46 payments
  3. EBGLYSS $10,339 12 payments
  4. DUPIXENT Immunology And Inflammation $9,187 11 payments
  5. TAPINAROF $7,500 3 payments
  6. OPZELURA $6,486 16 payments
  7. CIBINQO $5,527 13 payments
  8. Xolair $4,442 19 payments
  9. EUCRISA $3,087 22 payments
  10. RINVOQ $1,043 27 payments
  11. Other $4,284 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

423 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record